Keros Therapeutics, Inc.KROS
NASDAQ • Healthcare
$11.64
P/E
6.26
PEG
0.13
FCF Yield
—
Rev Growth YoY
-87.3% YoY
Gross Margin
-3.9%
Health Score
6/10
D/E Ratio
0.06
Confidence
—
Business Snapshot
Keros Therapeutics is a biotechnology company headquartered in the healthcare sector. Its TTM revenue of $244.06 million suggests it may have commercial-stage products or large partnership agreements, although the revenue is heavily concentrated in a single quarter. The company operates in a high-risk, binary-outcome industry where pipeline milestones and regulatory events drive valuation. With a current price of $11.64, well off its 52-week high of $22.55, the stock exhibits typical small-cap biotech volatility. A defining characteristic is its exceptionally low debt/equity ratio of 0.06x and a current ratio of 15.45x, indicating a fortress-like balance sheet that provides significant financial flexibility.
Financial Health
The gross margin stands at -3.9%, a severe deterioration from 97.2% in the prior year, signaling a fundamental shift in cost structure or revenue mix. The TTM net margin of 35.6% appears strong, but it is largely driven by a single quarter’s performance and may not be repeatable...